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[57] ABSTRACT
The present invention related to a sensitive method of
detecting t(14;18) translocations arising from variable
breakpoints in the J-region of the immunoglobulin
heavy chain locus on chromosome 14. These break-
points are typical abnormalities of human follicular
lymphomas. In particular, the invention utilizes a se-
quence amplification by polymerase chain reaction in
which primers are synthesized which are so designed
that one primer will always flank the breakpoint in the
J-region regardless of variation in the breakpoint. Con-
sequently, the invention is a highly sensitive tool to
detect minimal residual cells carrying the t(14;18) and
has potential to identify patients with subclinical dis-
ease.
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DETECTION OF MINIMAL NUMBERS OF
NEOPLASTIC CELLS CARRYING DNA
TRANSLOCATIONS BY DNA SEQUENCE
AMPLIFICATION
BACKGROUND OF THE INVENTION
Frequency of recurrence is one of the major prob-
lems in cancer treatment Relapse from clinically unde-
tectable residual disease is the most likely mechanism.
Detection of minimal disease is extremely difficult since
tumorspecific markers are not readily available. Molec-
ular technology has provided a means to demonstrate
residual disease by identifying clonal rearrangement
patterns that are present in malignant hematopoietic
cells (1). Southern blot hybridization detects neoplastic
cells at levels as low as 1% of the total numberofcells
(2). However, one of the major drawbacks in this situa-
tionis thatit is difficult to be certain that faint nongerm-
line bands indeed represent clonal rearrangements Fur-
thermore, no rearranged bandscan be detected in cases
in which the concentration of neoplastic cells is below
1%. Theoretically this occurs frequently while patients
are in remission.
The karyotypic abnormality, t(14;18)(q32;q21), has
been observed in approximately 90% of humanfollicu-
_ lar lymphomas (3-5). This translocation frequently re-
sults in rearrangement of a putative oncogene “bc1-2”
which resides at chromosome 18 band q21 (6). In the
majority of cases with the t(14;18), the molecular break-
points on chromosome 18q21 cluster within a 4.3 kilo-
base (kb) HindIII restriction fragment or more specifi-
cally a 2.8 kb EcoR1-Hind IH restriction fragment
which has recently been designated the t(14;18) major
breakpoint cluster region (mbr) (7-11). DNA sequenc-
ing of the crossoversites revealed that breakpoints on
chromosome 18q21 wereclustered within 150 base pairs
(bp) of each other and breakpoints on chromosome 14
werelocated close to the 5’ end of oneofthe joining (J)
segments (J1 to J6) of the immunoglobulin heavy chain
locus (JH) (11-13).
Saiki et al. have recently utilized a new technique,
sequence amplification by polymerase chain reaction
(PCR), to diagnose sickle cell anemia prenatally (14).
This technique is mainly applicable to genetic disorders
with a point DNA mutation.It is difficult to apply PCR
to the detection of chromosomal translocation because
of the variability of molecular breakpoints on chromo-
somes. The present invention describes a method of
utilizing the PCR technique to amplify DNA sequences
flanking the crossoversite of a chromosomal transloca-
tion such as t(14;18) which is characteristic of a tumor.
Since cells carrying the subject t(4;18) translocation are
unique to malignant hematopoietic cells, detection and
amplification of such sequences can be used as evidence
for minimal residual disease. The present invention also
demonstrates the unique consequence of applying the
PCR technique to a chromosomal translocation, Le,
preferential amplification of the hybrid DNA sequences
of the chromosomaltranslocation, but not the normal
DNAsequence.
SUMMARYOF THE INVENTION
The present invention involves a method fordetect-
ing minimal numbers ofneoplastic cells in an individual.
These neoplastic cells are typically residual cells from a
lymphomaincompletely eradicated by antitumor ther-














tion may be characterized by a DNAtranslocation
related to a specific chromosomal breakpointclustering
region. A neoplasm to whichthe present invention may
be applied is most typically a human follicular lym-
phomaalthough it may also be characterized as a non-
Hodgkin’s lymphoma, a pre-B-cell or B-cell leukemia, a
B-cell lymphoma,a largecell lymphoma,a diffuse large
cell lymphomaor a small noncleaved cell lymphoma.
The method of the present invention typically in-
cludes the following steps.
(1) Incubating a mixture comprising:
(a) deoxyribonucleotide triphosphates including
deoxyadenosine triphosphate, deoxythymidinetri-
phosphate, deoxycytosine triphosphate and deox-
yguanosine triphosphate;
(b) DNAfrom cells, most particularly lymphoid cells
from blood, bone marrow or lymph node of the
individual;
(c) DNA polymerase, preferably the Klenow frag-
mentofE. coli DNA polymerase or Thermus aquat-
icus DNA polymerase.
(d) a first oligonucleotide primer, said first primer
being identical to an upstream nucleotide sequence
flanking the coding DNAtranslocation, derived
from one chromosomesuch as chromosome 18q21.
(e) a second oligonucleotide primer, said second
primer being complementary to a downstream
nucleotide sequence flanking the coding DNA
translocation derived from the other chromosome,
such as chromosome 14q32. (The primersare pres-
ent in the incubation mixture in excess of that
needed to bind complementary oligonucleotide
sequences of the DNAandare preferably at about
a 1 micromolar (uM) concentration.).
The incubating is under conditions allowing anneal-
ing of the primers to the crossoversite of the chromo-
somal translocation DNA sequences and a substantial
portion of flanking DNA sequences.
(2) The incubating is then terminated by DNA dena-
turation. The cycles of annealing, synthesis and dena-
turation are repeated numeroustimes(preferably 20-50)
to facilitate duplications of the original and previously
synthesized translocated and substantial flanking DNA
sequences, The repetition is carried out in a manner
allowing exponential amplification of DNA sequences
extending from primers and including a DNA region
complementary to the other oligonucleotide primers.
This amplification is an extension of each primerto and
including a post-translocational DNA sequence com-
plementary to the other memberofthe primerset being
used.
(3) The exponentially amplified DNA is probed for
the presence of oligonucleotide sequences characteriz-
ing the translocation region. Elongation of each primer
in this system eventually involves the addition thereto
of a coding or non-coding translocation DNA sequence
usually terminating in the oligonucleotide complemen-
tary to the other memberofthe primerset being uti-
lized. Positive probings indicate the presence of neo-
plastic cells in the sample of the individual’s cells, since
DNAcharacterizing said neoplastic cells was specifi-
cally amplified and probed.
The above-described procedure may likewise be di-
rected to detection of neoplastic cells characterized by
DNAtranslocation related to more than one specific
breakpoint clustering regions. The method described
above could be modified as follows where more than
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one breakpoint clustering region may be being ampli-
fied and probed. The incubated mixture could have at
least two sets of oligonucleotide primers, each set flank-
ing a particular breakpointclustering region. Eachset
of oligonucleotide primersconsists ofa first oligonucle-
otide primer and a second oligonucleotide primer, said
first oligonucleotide primer being identical to an up-
stream coding nucleotide sequence flanking a particular
DNAbreakpoint clustering region of a chromosomal
translocation and said second primer being complemen-
tary to a downstream coding nucleotide sequenceflank-
ing the same particular DNA breakpoint clustering
region of this translocation. The mixture of primers,
DNA from cells, deoxynucleotide triphosphates and
DNA polymerase and the incubating is again under
conditions facilitating annealing of the primers to the
’ crossoversites of the translocations and synthesis of the
sequences of coding and non-coding translocation
DNAandincluding a substantial portion of flanking
DNA,sucha substantial portion including a DNA por-
tion complementary to the other memberofthe particu-
lar primer set being used. Again the incubating is termi-
nated by DNA denaturations. The annealing, synthesis
and denaturation are repeated in a cyclic manner to
facilitate further synthesis of the original DNA and of
newly synthesized DNA,said repeating being carried
out in a manner allowing exponential amplification of
DNA sequences between initiating oligonucleotide
primers and sequences complementary to the other
member of the primer set. Lastly, the exponentially
amplified DNA is probed for the presenceofoligonu-
cleotide sequences characterizing the translocation of
DNAsequence. Thepresenceofneoplastic cells in the
sample of the individual’s cells is identified by positive
probings. Such probings are most typically carried out
by Southern blot or Dot blot procedures whose meth-
odologies are well-known to those skilled in the rele-
vant arts. The method of the present invention involves
in vitro synthesis of the DNA sequencesat thecross-
oversite of a tumor characteristic chromosomal translo-
cation by primer extension and a substantial flanking
DNAregion including that nucleotide sequence com-
plementary to the primers.
The oligonucleotide primers utilized in the methods
of the present invention are preferably complementary
or identical to DNA sequences located within about
1000 bases of the nearest chromosomal breakpoint clus-
tering region. These oligonucleotide primers are further
preferably between about 12 and about 20 nucleotides in
length. .
The method of the present invention most particu-
larly involves detection of neoplasia such as those hav-
ing the t(14;18) translocation. These neoplasia charac-
teristically have a major breakpointclustering regionin
the majority of cases and a minor breakpoint clustering
region in the minority of the cases, the major breakpoint
clustering region being the mbr region and minor break-
point clustering region being the mcr region. In cases
where two breakpoint regions are to be analyzed, two
sets of oligonucleotide primers are added to the above
described incubation mixture and the probings are de-
rived from the crossoversites of the translocated DNA.
The probing step of the present invention, as men-
tioned above,typically involves Southern blot analysis
or Dotblot analysis. Such Southern blot analysis char-
acteristically includes gel electrophoresis of the PCR
amplified DNA segments, transfer of electrophoresed












probing the filter of nucleotide sequences binding the
probes of interest. Dot blot analysis is similar to the
above procedure except that the PCR-amplified DNA
is denatured in situ and then blotted to the filter without
gel electrophoresis.
The method of the present invention preferably in-
volves the detection of minimal numbers of neoplastic
cells with a chromosomal translocation. Such neoplas-
tic cells, particularly those characterized by a t(14;18)
chromosomal translocation are most frequently human
follicular lymphomas. Preferred subject neoplasia of the
present invention mayalso be characterized as being a
non-Hodgkin’s lymphoma, B-cell or pre-B cell leuke-
mia, B-cell lymphoma, large cell lymphoma, diffuse
large cell lymphoma or small noncleaved cell lym-
phoma.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 schematically illustrates preferential PCR
amplification of the hybrid 18q21-JH DNAsequence.
FIG. 2(A) shows a partial restriction enzyme map
surrounding the mbr region of chromosome 18 band
q2l; FIG. 2(B) shows Southern blot hybridization with
labeled mbr probe ofrestriction enzyme digested DNA
samples.
FIG.3 showsa Southern blot analysis of PCR-ampli-
fied genomic DNA with radioactively labeled primer
18q21(+) and primer Jz(—).
FIG. 4 shows a Southern blot analysis of PCR-ampli-
fied genomic DNAwith radioactively labeled oligonu-
cleotide 18q21(+)II.
DESCRIPTION OF THE PREFERRED
EMBODIMENT
The present invention involves using the polymerase
chain reaction (PCR) technique to amplify DNA se-
quencesthat flank the crossoversite of a chromosomal
translocation characteristic for follicular lymphomas,
t(14;18)(q32;q2l). This technique permitted the detec-
tion of cells carrying the t(14;18) hybrid DNA sequen-
ces at a dilution of 1:100,000. The remission marrow and
blood samplesofpatients with follicular lymphoma and
the t(14;18) fail to show any abnormality by morpholog-
ical examination and conventional Southern blot analy-
sis. However, the t(14;18) hybrid DNA sequences were
detected by the PCR technique. Thus, the present in-
vention described a highly sensitive tool to detect mini-
mal residual cells carrying the t(14;18) and has the po-
tential to identify a subpopulation of patients with sub-
clinical disease. This invention can also be used for the
early detection and rapid diagnosis of a neoplasm with
the t(14;18) as well as for the diagnosis of the t(14;18) by
using a small amount of DNA sample(at the level of
several nanograms(ng)).
Polymerase chain reaction (PCR) is a technique
which allows exponential amplification of the target
DNAsequences.It has been used for rapid diagnosis of
certain hereditary genetic disorders in which a point
DNAmutation is present and each individual cell con-
tains the same abnormality. The present invention in-
volves the first application of PCR to a chromosomal
translocation, thus, resulting in preferential amplifica-
tion of tumorspecific hybrid DNA sequencesin a mini-
mal numberofcells carrying a chromosomaltransloca-
tion among several hundred thousand normalcells.
Two synthetic oligonucleotides were prepared as
primers for PCR usage. These two primers were ex-
pected to flank the crossoversite of the t(14;18) in the
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majority of cases. Primer 18q21(+), 5’-TTTGACCTT-
TAG-3', was identical to the sequences of the
(+)-strand of chromosome 18q21 (11-13) and primer
Jn—), 3-CAGAGGAGTCCA-S’, was complemen-
tary to the sequences present in the 3’ end of each
(+)strand J segment (15). Therefore, this primeral-
ways flanks the breakpoint on the Jy region even
though the breakpointvaries from J1 to J6 from case to
case. In case of the t(14;18), copies of the (+)-strand
hybrid 18q21-Jx DNA sequences were synthesized
from primer 18q21(+-) and copies of the (-)-strand hy-
brid 18q21-;H DNAsequences were synthesized from
primer Jx(—). New copies of the (+)-strand and the
(—)-strand hybrid 18q21-Jx DNA sequences in turn
became templates of primer J;{—)and primer 18q21(+-)
respectively. Therefore, DNA sequences flanking the
Crossoversite of the t(14;18) were amplified exponen-
tially as PCR was carried out (FIG. 1A). In contrast,
such amplification could notbe generated in cases with-
out the t(14;18) because no new templates for the prim-
ers could be synthesized (FIG. 1B). These two primers
could also be used as probes to detect newly synthesized
hybrid 18q21-;H DNA sequences, which were gener-
ated in case of the t(14;18), but not the new copies of
18q21(+-) or Jx(—) DNA sequences which were syn-
thesized in cases without the t(14;18). Another oligonu-
cleotide 18q21(+)IL, 5'-CACAGACCCACC-
CAGAGCCC.3’, deduced from the mbr region {27
bases 3’ to the primer 18q21(+-)], was used as an “inter-
nal” probe to further confirm that the PCR amplified
DNAsegmentscontained the hybrid 18q21-J sequen-
ces (11-13). Since 18q21(+)II derived from sequences
of the (+)-strand chromosome 18q21,it cannot hybrid-
ize with sequences extended from primer 18q21(+). In
contrast, it will hybridize with sequences extended from
primer Jz(—) in case of the t(14;18). Therefore, signals
detected by the radiolabeled 18q21(+)II probe strongly
indicate presence ofthe hybrid 18q21-J sequences.
FIG. 1 schematically illustrates the mechanism by
which PCRpreferentially amplifies the hybrid 18q21-
JH DNA sequences, but not the normal DNA sequen-
ces. As shownin FIG. 1(A), in cases of the t(14;18), the
hybrid 18q21-Jz{+) and 18q21(+)-JH(—) DNA se-
quences were synthesized from primer 18q21(+) and
primer JH(—) respectively. The primers are also com-
plementary to the newly synthesized hybrid 18q21-
JH(+) DNA sequences which, in turn, become tem-
plates for the primers. Therefore, exponential amplifica-
tion of the hybrid 18q21-JH(+) DNA sequences are
generated, i.e., Y=(1+E)\ where Y is the extent of
yield, E is the mean efficiency per PCR cycle and N is
the number of PCR cycles carried out. Presuming
E=100% and N=20,the final yield is 220 copies of
hybrid 18q21-JH(+) DNA sequences.
As shownin FIG.1(B), in case of normal karyotype,
the newly synthesized 18q21(+) and JH(—) DNAse-
quences can not be templates for the primers. There-
fore, the final yield was calculated as the following
formula: y=2n Xe, where y is the extent ofyield,
n
is
the number of PCR cycles and
e
is the mean efficiency
per cycle.
By means of DNAsequencing, about 60% offollicu-
lar lymphomas have been shownto have breakpoints on
chromosome 18q21 tightly clustered within 150 base
pairs of each other, which is named the molecular
breakpoint hot spot (11-13). Our primer 18q21(+-) was
derived from the (+)-strand DNA sequence of chromo-
some 18q21 immediately 5’ to the molecular breakpoint
6
hot spot. One “internal” probe, 18q21(+)II, was de-
tived from the (+)-strand 18q21 DNA sequence 27
bases 3’ to primer 18q21(+). The breakpoint on chro-
mosome 1432is also very consistent from case to case.
It always occurs at the 5’ end of one of the J-segments
(J1-J6) of the immunoglobulin heavy chain gene. Since
the sequences at the 3’ end of each J-segmentare the










this region was made. Therefore, Primer Jz(—) would
always anneal to the crossoversite of the t(14;18) even
though the breakpoints on chromosome 14q32 vary
from J1 to J6 from case to case.
In order to establish the use of PCR to amplify the
DNA sequences flanking the crossover sites of the
t(14;18), three representative DNA samples were se-
lected. Sample A was from a lymph nodeoffollicular
lymphoma with the t(14;18) breakpoint occurring
within the mbr region. Sample B was from a lymph
node of reactive lymphadenitis with normal karyotype
Sample C as from a lymph nodeoffollicular lymphoma
with the t(14;18) breakpoint 3’ to the mbr region. These
samples were analyzed by Southern blot hybridization
with a human genomic DNA fragmentspecific for the
mbr region of chromosome 18q21 (FIG. 2A) (7,11). As
shownin FIG.2B, Lanes 1 and 4, two rearranged bands
were detected in Sample A, indicatingthe breakpoint
on chromosome 18q21 occurring within mbr. In Sample
C only one rearranged band was detected byrestriction
endonuclease Sst1 and no rearrangement was detected
with HindIII (FIG. 2B, Lanes 3 and 6). Therefore, the
breakpoint occurred 3’ to mbr (within the Hind III-Sst1
restriction fragment).
FIG. 2(A) showsa partial restriction enzyme map
surrounding the mbr region of chromosome 18 band
q21. The solid bar represents the germline DNA struc-
ture of chromosome 18 band q21 (7). The horizontal
line labeled as mbr indicates the t(14;18) major break-
point cluster region and the probe used for Southern
blot hybridization to map the chromosomal breakpoints *
of the t(14;18) on chromosome 18q21. Theasterisk (*)
indicates the t(14;18) breakpoint hot spot where primer
18q21(+-) was deduced (1,13). (B) Southern blot hy-
bridization with mbr probe. DNA’s weredigested with
enzyme Sstl or enzyme HindIII and size fractionated
on a 0.8% agarosegel, transferred to a nylonfilter, and
hybridized with a radiolabeled mbr probe. The rear-
ranged bandsare indicated by arrows. Lanes 1-3 were
Sst1 digested Sample A, B and C respectively. Lanes
4-6 were HindIII digested Sample A, B and C respec-
tively. Lanes 7-10 were DNA samples obtained from
Patient 1 and were digested with enzyme HindIII (Lane
7: pretreatment bone marrow sample obtained in Octo-
ber of 1985; Lane 8: remission blood sample obtained in
June of 1986; Lane 9: remission marrow sample ob-
tained in June of 1986); Lane 10: remission marrow
sample obtained in September of 1986). Lane 11 and 12
were DNA samples obtained from Patient 2 and were
digested with HindIII. (Lane 11: pretreatment lymph
node sample obtained in January of 1986; Lane 12:re-
mission marrow sample obtained in October ef 1986).
These rearranged bands in Sample A and
C
also
comigrated with the immunoglobulin JH gene, which
confirmed that breakpoint on chromosome14relocated
in the Jyregion. These three samples were subjected to
PCR. The hybrid 18q21-J;,; DNA sequences in Sample
A were amplified and the signals were detected after
the 15th cycle by radiolabeled primers 18q21 and Jy
(FIG. 3A). The amplified DNA segments also hybrid-
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ized with radiolabeled 18q21(+-)II, which further con-
firmed presenceofthe hybrid 18q21-J7sequences (FIG.
4, Lanes 1-3). Sample B was not amplifiable because
there were no hybrid 18q21-J;DNA sequences present.
Sample C could not be amplified because primer
18q21(+) was too far upstream (>ikb) from the break-
point. Since approximately 60% offollicular lymphoma
samples were mapped to have the t(14;18) breakpoint
occurring within the mbr region (8,10), it was estimated
that close to 60% offollicular lymphomas will be am-
plifiable by the above described specific PCR tech-
nique.
Another manipulation was performed to show that
the PCR-related method ofthe present invention could
preferentially amplify the hybrid 18q21-Jz DNA se-
quences, but not the normal DNA sequences. Dilutions
of Sample A and Sample B in different ratios, 1:100,
1:5,000, and 1:100,000, were subjected to PCR.In the
first two instances, the hybrid 18q21-J7DNA sequences
were amplified and signals were detected after the 20th
cycle of PCR as shownin FIG. 3B and FIG. 4, Lane 4.
In the last instance (1:100,000 dilution), a strong and
convincing signal was detected at the 30th cycle by
using a mixture of radiolabeled primers 18q21(+) and
Ji—) as a probe (FIG. 3C, Lane 3). The presence of
the hybrid 18q21-Jz sequence was also further con-
firmed by the radiolabeled “internal” probe
18q21(+)IL.
FIG.3 shows a Southern blot analysis of PCR ampli-
fied genomic DNA with radiolabeled primer 18q21(+)
and primer J7{—). Samples (lug) of genomic DNA
were dispensed in microcentrifuge tubes then denatured
at 100° C. for 5 minutes, centrifuged for 10 seconds to
remove the condensation, and adjusted to 100 ul in a
buffer containing 10 mMtris, pH 7.5, 50 mM NaCl, 10
mM MgCl, 1.5 mM deOxynucleotide triphosphate
(each of 4 was used), 1 uM primer 18q21(+) and 1 uM
primer J4(—). The samples were then transferred to a
42° C. heat block for 2 minutes to allow annealing,
followed by adding 1 ul of the Kienow fragmentof E.
coli DNA polymerase I (1 unit/ul) and 1 ul of 0.1 M
dithiothreitol (DTT) and allowing extension of DNA
sequencesfor 5 minutes. The cycle—denaturation, rean-
nealing and extension—was repeated for 19 to 29 more
times as needed, except that subsequent denaturations
were performed at 95° C. for 2 minutes. Amplified
DNA(amplimers) from the PCR equivalent to 25 nano-
grams (ng) of the original DNA’s was loaded on a 2%
alkaline agarose minigel, fractionated by electrophore-
sis (SOV) for 2 hours, and then neutralized and trans-
ferred to a nylonfilter. Prehybridization, hybridization
and washingoffilters were carried out as described by
Saiki et al. (14). A mixture of primer 18q21(+-) and
Ji—) was radiolabeled with [gamma-22P]ATP to a
specific radioactivity of >3uCi/pmol (microcurie/-
picomole) oligonucleotide and used as a probe. Autora-
diography was carried out with a single intensification
screen at —-70° C. for 48 hours. (A) 1 microgram (ug) of
HindIII-digested Sample A (Lane 1) was compared
with 25 ng of PCR amplified Sample A at varioustime
points: the third cycle (Lane 2), the 7th cycle (Lane 3),
the 10th cycle (Lane 4), the 15th cycle (Lane §) and the
20th cycle (Lane 6). (B) Dilutions of Sample A and
Sample B in different ratios (1:100 and 1:5,000) were
subjected to PCR and 25 ng of PCR amplified DNA’s
werecollected at various time points: Lanes 1-4 repre-
sent mixtures of 1:100 dilution amplified for 10, 15, 20















of 1:5,000 dilution amplified for 15, 20, 25, 30 cycles
respectively. (C) Lane 1: Sample B subjected to PCR
for 30 cycles; Lanes 2 and 3: Mixture of Samples A and
B in 1:100,000 ratio amplified for 20 and 20 cycles of
PCR respectively; Lanes 4-6: remission marrow and
blood samples were obtained from Patient 1 and sub-
jected to PCR for 27 cycles, corresponding to samples
shownin FIG. 2, Lanes 8-10 respectively; Lane 7: pre-
treatment tumor sample obtained from Patient 2 and
amplified for 20 cycles of PCR: Lane 8: remission mar-
row sample obtained from Patient 2 and subjected to
PCR for 27 cycles. The #X174 HaelIlI molecular
weight markersare labeled on the left of each autoradi-
ograph.
FIG.4 shows a Southern blot analysis of PCR ampli-
fied genomic DNA with radiolabeled oligonucleotide
18q21(+)II. The PCR, radiolabeling, hybridization
condition washing condition and autoradiography were
carried out as described above except that the radiola-
beled oligonucleotide 18q21(+)II with specific activity
of >3uCi/pmol was used and a probe and autoradiog-
raphy was carried out for 20 hours. Lanes 1, 2 and 3: 25
ng of Sample A’s were amplified for 20, 25 and 30 cy-
cles respectively. Lane 4: 25 ng of mixture of Sample A
and Sample B in 1:5,000 dilution were subjected to PCR
for 40 cycles. Lane 5 and 6: 25 ng of remission marrow
samples obtained from Patient 1 in June and September
of 1986 respectively were amplified for 40 cycles. The
x174 HaellI molecular weight markers are labeled on
the left of the autoradiograph shownin FIG. 4.
Sequential follow-up studies in two patients with
follicular lymphomaandthe t(14;18) translocation were
performed. The pretreatment tumor samples were
shown to have chromosomal breakpoints occurring
within mbr (FIG. 2B, Lanes 7 and 11). The remission
marrow and blood samples obtained from these two
patients were first analyzed by morphological examina-
tion and conventional Southern blot hybridization with
a radiolabeled mbr probe. All the samples appeared
normal since none of them demonstrated any morpho-
logic abnormality or rearranged bands (FIG.2B, Lanes
8-10 and 12). However, hybrid DNA sequences were
markedly amplified and thus clearly detected by the
PCR technique in samples obtained from Patient 1
(FIG. 3C, Lanes 4-6 and FIG. 4, Lanes 5 and 6) indicat-
ing the presenceofresidual neoplastic cells carrying the
t(14;18), Even though the hybrid 18q21-Jz DNA se-
quences were amplifiable in the pretreatment tumor
sample obtained from Patient 2 (FIG. 3C, Lane 7), no
hybrid DNAsequences were detected in the remission
marrow sample by the PCR technique (FIG. 3C, Lane
8). These findings indicated that the concentration of
neoplastic cells carrying the t(14;18) was too low to be
detected by our current techniques or the patient was
completely free of tumor and there was no t(14;18)
target DNA sequences present for amplification.
In addition to the major breakpoint clustering region
(mbr) observed in about 60% offollicular lymphoma,a
new breakpoint clustering region (mcr) in the t(14;18)
translocation has recently been described in about 30%
of follicular lymphomas (16). Using proper primers
derived from this region, the technique of the present
invention may be applied to samples with the t(14;18)
breakpoint occurring within this region. Furthermore,
the t(14;18) has also been observed in about 20-40% of
diffuse large cell lymphoma and 20% of small non-
cleaved cell lymphoma(9,16). Therefore, this technique
canalso be applied to subtypes of malignant lymphomas
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with the t(14;18) translocation besides follicular lym-
phoma. Finally, this technique can be applied to any
chromosomal translocation if the breakpoints on both
chromosomes are limited to a small DNA segment
(about one kilobase), such as the t(11;14) translocation.
Utilizing the PCR technique of the present invention
in a preferred application, a fundamental and very im-
portant question was addressed, i.e., were there small
numbers of circulating cells carrying the t(14;18) in
patients with follicular lymphoma in early clinical
stages of disease and in clinical remission?
Ten blood samples from patients with follicular lym-
phomaand the t(14;18) breakpoint within the mbr re-
10
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there was clinically detectable disease, there were small
numbers of cells carrying the t(14;18) in circulation.
The most intriguing finding was that even when pa-
tients achieved complete remission, circulating cells
carrying the t(14;18) were detected in 4 out of 5 in-
stances by the PCRassay.
The technique of the present invention was also used
to determine whether there were circulating cells with
the t(14;18) in an early clinical stage of the disease. As
shown in Table II, three pretreatment blood samples
from 3 patients whose lymph nodes. Were known to




DETECTION OF LYMPHOMAIN PERIPHERAL
BLOOD BY THE PCR TECHNIQUE




WITHIN mbr NOT STUDIED
ANN ARBOR PATIENTS PATIENTS PATIENTS PATIENTS
STAGE STUDIED POSITIVE STUDIED POSITIVE
I 0 0 2 4d
ul i 1 4 3
III 0 0 3 3
IV 2 2 1 i
TOTAL 3 3 10 8
gion were initially selected. These samples were ob-
tained in various clinical states: 3, before treatment, 2, at
partial remission and 5, at complete remission. Morpho-
logically these samples appeared normal. They were
analyzed both by the PCR assay and Southern blot
analysis (Table I).
TABLE I
DETECTION OF LYMPHOMAIN PERIPHERAL
BLOOD BY THE PCR TECHNIQUE
CORRELATION WITH SOUTHERN BLOT
ANALYSIS ACCORDING TO CLINICAL STATUS
 
   
CLINICAL PATIENTS POSITIVE POSITIVE
STATUS STUDIED BYPCR BY SOUTHERN
BEFORE 3 3 1
TREATMENT
PARTIAL 2 2 0
REMISSION
COMPLETE 5 _4 1
REMISSION
TOTAL 10 9 2
Among the 10 samples analyzed, 9 were positive for the
translocation by the PCR assay. In contrast, clonal
bcl-2 gene rearrangement could be detected in only 2
cases by traditional Southern blot analysis. Three out of
3 samples obtained before treatment and 2 out of 2
samples obtained at partial remission were positive by




All three of these samples were positive by the present
PCRassay. In correlation with the clinical stage, one
was from stage II disease and the other 2 were from
stage IV disease. Ten pretreatment blood samples were
analyzed from 10 patients for whom no DNA samples
from the lymph nodes were available to study. Since
about 60% offollicular lymphomas havethe breakpoint
within the mbr region, it was expected that approxi-
mately 60% of blood samples should be amplifiable if
involving a lymphoma. As shownin Table II, 8 out of
these 10 samples were positive. Even in the 6 samples
obtained from clinical stage I or stage II disease, 4 were
positive. The reason for the remaining being negative
was most likely due to absence of a breakpoint within
the mbr region. These findings strongly indicated that
follicular lymphoma was a systemic disease despite the
fact that the disease might be localized clinically.
To study the mechanism of frequent recurrences
observed in follicular lymphoma, blood samples ob-
tained from patients in clinical remission at various time
points of the remission were analyzed by the PCR as-
say. As shownin Table III, five samples were obtained
from patients at the time of remission of less than one
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YEARS IN WITHIN MBR BREAKPOINT NOT
CONTINUOUS PATIENTS PATIENTS PATIENTS PATIENTS
REMISSION STUDIED POSITIVE STUDIED POSITIVE
>1 YEAR 5 4 1 i
2-3 YEARS 0 0 3 2
TOTAL 5 4 4 3
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Fourof these 5 patients showed evidence of subclinical
disease by the PCRassay. Similarly in the 4 cases in
whom the breakpoint was not studied, 3 were positive.
In these 3 instances, 2 had been in remission for more
than 2 years. These findings suggested that continuous
relapse of follicular lymphoma may be due to recur-
rence of minimal residual disease which progresses
slowly. .
It may be that the PCR assay can reliably predict the
likelihood of future relapse patients in remission. There
were 5 complete responders in remission who had been
followed clinically for more than 8 months after the
results of the PCR assay were available. As shown in
Table IV,in the 4 patients whose remission blood sam-
ples were positive, 3 have relapsed: 2 relapsed clinically
and 1 developed clonal bcl-2 gene rearrangement as
shown by Southern blot procedures.
TABLE IV
DETECTION OF LYMPHOMAIN
PERIPHERAL BLOOD BY THE PCR
TECHNIQUE IN COMPLETE RESPONDERS
CLINICAL OUTCOME
ACCORDING TO RESULTS OF PCR ASSAY
RESULTS OF NUMBER OF OUTCOME
 
PCR ASSAY PATIENTS RELAPSE REMISSION
POSITIVE 4 3 I
NEGATIVE 1 0 1
 
The remaining onepatientis still in remission while
on maintenance therapy. The only one patient whose
remission blood sample was negative has been in contin-
uous remission for more than 20 months.Since the pre-
treatment sample was amplifiable in this patient, possi-
ble explanations for the remission sample being negative
may be that either the number of neoplastic cells was
too small to be detected or the patient was completely
free of tumor.
Thefeasibility of using the PCR techniqueto detect
minimal numbers of neoplastic cells carrying a chromo-
somal translocation was established by the methods of
the present invention. Detection of small numbers of
circulating monoclonal B cells by flow cytometry or
clonal immunoglobulin gene rearrangementin patients
with follicular lymphoma in remission has been re-
ported (1,17). The sensitivity of the methods of the
present invention far exceeds the sensitivity limit
achieved by conventional Southern blot analysis or the
flow cytometric method. Detection of minimal neoplas-
tic cells with chromosomal translocation by meansof:
PCRwill makeit possible to address several important
biological and clinical questions that could not be an-
swered before. For example, do patients in long term
remission have quiescent tumorcells with proliferative
potential? Can detection of minimal residual tumorcells
predict early relapse? Do patients with persistent mini-
mal residual disease after prolonged treatment require
non-cross resistant therapy to prevent relapse? The
answers will help in understanding tumor biology and
designing strategies for cancer treatment.
The following cited articles are incorporated by ref-
erence herein for the reason cited.
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9. MS Leeet al., Blood, 70:90 (1987).
10. ML Cleary, J Sklar, Proc. Natl. Acad. Sci. USA,
82:7439 (1985).
11. ML Cleary, SD Smith, J Sklar, Cell, 47:19 (1986).
12. Y Tsujimoto, J Gorham, J Cossman, E Jaffe, CM
Croce, Science, 229:1390 (1985).
13. Y Tsujimoto, CM Croce, Proc. Natl. Acad. Sci.
USA,83:5214 (1986).
14. RK Saiki et al., Science, 230:1350 (1985).
15. JV Ravetch, U Siebenlist, S Korsmeyer, T Wald-
man, P Leder, Cell, 27:583 (1981).
16. Weiss et al., N. Engl. J. Med., 317:1185
17. BR Smith et al., N. Engl. J. Med., 311:1476 (1984).
Changes may be madein the operation and arrange-
ment of the various elements, steps and procedures
described herein without departing from the concept
and scope ofthe invention as defined in the following
claims.
Whatis claimedis:
1. A method for detecting neoplastic cells in an indi-
vidual, said neoplastic cells being characterized by a
t(14;18) chromosomal translocation related to a specific
breakpoint clustering region, the method comprising
the steps of:
incubating a mixture comprising deoxyribonucleotide
triphosphates, DNA from acell sample ofthe indi-
vidual, DNA polymerase, a first oligonucleotide
primer and a second oligonucleotide primer, con-
sisting essentially of - base sequence 5’-
TTTGACCTTTAG-3oran oligonucleotide com-
peting with said first primer for hybridizing to at
least a portion of (—)-strand DNA of chromosome
18q21 immediately 5’ to a molecular breakpoint hot
spot region located in exon 3 and said second
primer consisting essentially of base sequence 3’-
CAGAGGAGTCCA-S’ or an_ oligonuleotide
competing with said second primerfor hybridizing
to a sequence 3’ to an end of segment Jyzof chromo-
some 14 immunoglobulin heavy chain gene
wherein is located a breakpoint clustering region,
said incubating promoting annealing of the primers
to the translocation crossoversite and synthesis of
coding or non-coding translocation DNA sequen-
ces and a substantial portion of flanking DNAse-
quences, the incubation then being terminated by
DNAdenaturation;
repeating said incubation step without addingfurther
cell sample in a cyclic mannertofacilitate duplica-
tion of the original and newly synthesized translo-
cated and substantial flanking DNA sequences,said
repeating being carried out in a manner exponen-
tially amplifying DNA sequences between and
including DNA regions complementaryto thefirst
and second oligonucleotide primers; and
analyzing the exponentially amplified DNA for oligo-
nucleotide sequences characterizing the transloca-
tion region by separating the exponentially ampli-
fied DNA and hybridizing the amplified DNA.
with the first and second primers and identifying
neoplastic cells by the presence of said sequences.
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2. A method for detecting a t(14;18) translocation in
neoplastic cells in an individual, said translocation de-
rived from region J of chromosome 14 immunoglobulin
heavy chain gene, the method comprising the stepsof:
incubating a mixture comprising deoxyribonucleotide
triphosphates, a DNA samplefromtissue orcells of
the individual, DNA polymerase andat least one
set of oligonucleotide primers, each set of oligonu-
cleotide primers consisting of a first oligonucteo-
tide primer and a second oligonucleotide primer,
said first oligonucleotide primer consisting essen-
tially of base sequence 5’-TITGACCTTTAG-3’
or an oligonucleotide competing with said first
primerfor hybridizing to (—)-strand DNA of chro-
mosome 18q21 within 1000 base pairs 5’ to mbr and
said second primer consisting essentially of base
sequence 3'-CAGAGGAGTCCA-5' or an oligo-
nucleotide competing with said second primer for
hybridizing to a sequence 3’ to the immunoglobulin
heavy chain chromosome 14 Jy region breakpoint
saidincubating being under conditions promoting
annealing of the primers to the crossoversites of
the translocation, the incubation then being termi-
nated by DNA denaturation;
repeating said incubation step without further adding
of cell sample in a cyclic manner tofacilitate fur-
ther synthesis of the original DNA and of newly
synthesized DNA,said repeating being carried out
in a mannerfacilitating repeated primer extensions
and exponential amplification ofDNA sequencesat
the crossoversites of the translocations;
separating amplified DNA byfractionation means;
hybridizing the exponentially amplified DNA with a
probe wherein the probe base sequenceis identical
to at least a portion of 18q21(+-) at a point 3’ to the
first primer; and
analyzing the hybridized exponentially amplified
DNAfor the presence of oligonucleotide sequen-
ces characterizing the t(14;18) translocation region
andidentifying therefrom the presence of neoplas-
tic cells by the presence of said sequences.
3. The method of claim 1 wherein thefirst and second
primer nucleotide sequences are located within about
1000 bases from the nearest breakpoint clustering re-
gion.
4. The method ofclaim 1 wherein the oligonucleotide
primers are each defined furtheras being from between
about 12 and about 20 nucleotides in length.
5. The method of claim 1 wherein thereis a single
breakpoint clustering region.
6. The method of claim 1 or 2 wherein the transloca-
tion is defined further as involving a t(14;18) transloca-
tion.
7. The method of claim 2 wherein there are two or
more breakpoint clustering regions to be analyzed.
8. The method of claim 2 wherein there is a major












9. The method of claim 8 wherein said major break-
point clustering region is the mbr region and said minor
breakpointclustering region being the mcrregion.
10. The method of claim 2 wherein there are at least
two breakpoint regions to be analyzed, two setsofoli-
gonucleotide primers are added to the mixture and the
probing is defined further as involving probes with
sequences derived from the crossoversites of the trans-
located DNAs.
11. The method of claim 1 or 2 wherein the probing
step is defined further as involving Southern blot analy-
sis.
12. The method of claim 1 or 2 wherein the incubat-
ing step is followed by a terminating step andthese steps
are repeated from about 20 to about 50 times to expo-
nentially amplify DNA flanked by oligonucleotide
primers.
13. The method of claim 1 or claim 2 wherein the
extension of a primerincludes synthesis oftranslocation
sequences and a substantial flanking DNA region in-
cluding that nucleotide sequence complementary to the
other primer.
14, The method of claim 12 wherein the terminating
step involves denaturation of DNA templates.
15. The method of claim 1 or 2 wherein the neoplasm
is humanfollicular lymphoma.
16. The method of claim 1 or 2 wherein the neoplasm
is a non-Hodgkin’s lymphoma.
17. The method of claim 1 or 2 wherein the neoplasm
is a B-cell lymphoma.
18. The method of claim 1 or 2 wherein the neoplasm
is a large cell lymphoma,a diffuse large cell lymphoma,
a small noncleaved cell lymphoma, a B-cell leukemia or
a Pre-B-cell leukemia. .
19. The method of claim 1 or 2 wherein the cell sam-
ple of the individual comprises neoplastic cells.
20. The method ofclaim 1 or 2 wherein the deoxynu-
cleotide phosphates include deoxyadenosine triphos-
‘phate, deoxythymidine triphosphate, deoxycytosine
triphosphate and deoxyguanosine triphosphate.
21. The method of claim 1 or 2 wherein the DNA
polymerase is the Klenow fragment of E. coli DNA
polymerase or Thermus aquaticus DNA polymerase.
22. The method of claim 1 or 2 wherein the primers
are at about 1 micromolar concentration.
23. The method of claim 1 or 2 wherein the chromo-
somal translocation is characterized by the breakpoints
at both chromosomeclustering within several hundred
base pairs.
24. The method of claim 1 wherein thefirst primeris
identical to sequences of chromosome 18q21(+) and
wherein said sequencesare 5' to or in the mbrregion.
25. The method ofclaim 1 wherein the second primer
‘is complementary to sequences in each (+)-strand J
segment occurring in the immunoglobulin heavy chain
at the 3’ end.
26. The method of claim 2 wherein the probe has the
sequence 5’-CACAGACCCACCCAGAGCCC:3’.
*x * x * *
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